Celiac disease: A challenging disease for pharmaceutical scientists

Pharmaceutical Research

Volumn 30, Issue 3, 2013, Pages 619-626

  Matoori, Simon ^a   Fuhrmann, Gregor ^a   Leroux, Jean Christophe ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

adjuvant therapy; autoimmune disorder; celiac sprue; drug formulation; polymeric drug

Indexed keywords

AGENTS USED IN INFLAMMATORY BOWEL DISEASE; ALV 003; AMG 714; ANTIINFLAMMATORY AGENT; BUDESONIDE; ENZYME INHIBITOR; GLUTEN; HLA BLOCKER; INFLIXIMAB; LARAZOTIDE; NEXVAX 2 VACCINE; PLACEBO; POLYMER; TRANSGLUTAMINASE 2 INHIBITOR; UNCLASSIFIED DRUG;

CELIAC DISEASE; CELL MEMBRANE PERMEABILITY; CLINICAL FEATURE; CROHN DISEASE; CYTOKINE RELEASE; DESENSITIZATION; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG EFFICACY; ENTERITIS; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYMPTOM; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELIAC DISEASE; DIET, GLUTEN-FREE; ENZYME INHIBITORS; ENZYME THERAPY; GLUTENS; GTP-BINDING PROTEINS; HLA-DQ ANTIGENS; HUMANS; PERMEABILITY; TRANSGLUTAMINASES;

EID: 84878852807     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0951-x     Document Type: Review

References (67)

1. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PHR, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2012. doi: 10.1136/gutjnl-2011-301346.
2. Tack GJ, Verbeek WHM, Schreurs MWJ, Mulder CJJ. The spectrum of celiac disease: epidemiology, clinical aspects and treatment. Nat Rev Gastroenterol Hepatol. 2010;7(4):204-13.
3. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol. 2002;2(9):647-55.
4. Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE. The prevalence of celiac disease in the United States. Am J Gastroenterol. 2012;107(10):1538-44.
5. Catassi C, Kryszak D, Bhatti B, Sturgeon C, Helzlsouer K, Clipp SL, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42(7):530-8.
6. Rewers M, Eisenbarth GS. Autoimmunity: celiac disease in T1DM-the need to look long term. Nat Rev Endocrinol. 2012;8(1):7-8.
7. Di Sabatino A, Corazza GR. Coeliac disease. Lancet. 2009;373(9673):1480- 93.
8. Pinier M, Fuhrmann G, Verdu E, Leroux J-C. Prevention measures and exploratory pharmacological treatments of celiac disease. Am J Gastroenterol. 2010;105(12):2551-61.
9. Ciccocioppo R, Di Sabatino A, Corazza GR. The immune recognition of gluten in coeliac disease. Clin Exp Immunol. 2005;140(3):408-16.
10. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297(5590):2275-9.
11. Heyman M, Abed J, Lebreton C, Cerf-Bensussan N. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut. 2012;61(9):1355-64.
12. Fasano A. Leaky gut and autoimmune diseases. Clin Rev Allergy Immunol. 2012;42(1):71-8.
13. Lebreton C, Ménard S, Abed J, Moura IC, Coppo R, Dugave C, et al. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology. 2012;143(3):698-707.
14. Molberg Ø, McAdam S, Lundin KEA, Kristiansen C, Arentz-Hansen H, Kett K, et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol. 2001;31(5):1317-23.
15. Di Sabatino A, Vanoli A, Giuffrida P, Luinetti O, Solcia E, Corazza GR. The function of tissue transglutaminase in celiac disease. Autoimmun Rev. 2012;11(10):746-53.
16. Meresse B, Malamut G, Cerf-Bensussan N. Celiac disease: an immunological jigsaw. Immunity. 2012;36(6):907-19.
17. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Auricchio S, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet. 2003;362(9377):30-7.
18. Abadie V, Discepolo V, Jabri B. Intraepithelial lymphocytes in celiac disease immunopathology. Semin Immunopathol. 2012;34(4):551-66.
19. DePaolo RW, Abadie V, Tang F, Fehlner-Peach H, Hall JA, Wang W, et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature. 2011;471(7337):220-4.
20. Sapone A, Bai J, Ciacci C, Dolinsek J, Green P, Hadjivassiliou M, et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012;10(1):13.
21. Fasano A. Clinical presentation of celiac disease in the pediatric population. Gastroenterology. 2005;128(4):S68-73.
22. Sapone A, Lammers K, Casolaro V, Cammarota M, Giuliano M, De Rosa M, et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med. 2011;9(1):23.
23. Ahn R, Ding YC, Murray J, Fasano A, Green PHR, Neuhausen SL, et al. Association analysis of the extended MHC region in celiac disease implicates multiple independent susceptibility loci. PLoS One. 2012;7(5):e36926.
24. Sollid LM, Khosla C. Novel therapies for coeliac disease. J Intern Med. 2011;269(6):604-13.
25. Trynka G, Wijmenga C, van Heel DA. A genetic perspective on coeliac disease. Trends Mol Med. 2010;16(11):537-50.
26. Lindfors K, Koskinen O, Kaukinen K. An update on the diagnostics of celiac disease. Int Rev Immunol. 2011;30(4):185-96.
27. Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136-60.
28. Barratt SM, Leeds JS, Sanders DS. Quality of life in coeliac disease is determined by perceived degree of difficulty adhering to a gluten-free diet, not the level of dietary adherence ultimately achieved. J Gastrointest Liver Dis. 2011;20(3):241-5.
29. Tio M, Cox MR, Eslick GD. Meta-analysis: coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy. Aliment Pharmacol Ther. 2012;35(5):540-51.
30. Stoven S, Murray JA, Marietta E. Celiac disease: advances in treatment via gluten modification. Clin Gastroenterol Hepatol. 2012;10(8):859-62.
31. Rashtak S, Murray JA. Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol Ther. 2012;35(7):768-81.
32. Keech CL, Dromey J, Chen Z, Anderson RP, McCluskey J. Immune tolerance induced by peptide immunotherapy in an HLA Dq2-dependent mouse model of gluten immunity. Gastroenterology. 2009;136(5):A-57.
33. Brown GJ, Daveson J, Marjason JK, Ffrench RA, Smith D, Sullivan M, et al. A phase I study to determine safety, tolerability and bioactivity of Nexvax2® in HLA DQ2+ volunteers with celiac disease following a long-term, strict gluten-free diet. Gastroenterology. 2011;140(5):S-437-8.
34. Daveson AJ, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A, et al. Effect of hookworm infection on wheat challenge in celiac disease - a randomised double-blinded placebo controlled trial. PLoS One. 2011;6(3):e17366.
35. McSorley HJ, Gaze S, Daveson J, Jones D, Anderson RP, Clouston A, et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One. 2011;6(9):e24092.
36. Bertrand N, Gauthier MA, Bouvet C, Moreau P, Petitjean A, Leroux J-C, et al. New pharmaceutical applications for macromolecular binders. J Control Release. 2011;155(2):200-10.
37. Pinier M, Verdu EF, Nasser-Eddine M, David CS, Vézina A, Rivard N, et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology. 2009;136(1):288-98.
38. Pinier M, Fuhrmann G, Galipeau HJ, Rivard N, Murray JA, David CS, et al. The copolymer P(HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology. 2012;142(2):316-25.
39. Marti T, Molberg Ø, Li Q, Gray GM, Khosla C, Sollid LM. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther. 2005;312(1):19-26.
40. Stenman SM, Venäläinen JI, Lindfors K, Auriola S, Mauriala T, Kaukovirta-Norja A, et al. Enzymatic detoxification of gluten by germinating wheat proteases: implications for new treatment of celiac disease. Ann Med. 2009;41(5):390-400.
41. Fuhrmann G, Leroux J-C. In vitro evaluation of the stability of proline-specific endopeptidases under simulated gastrointestinal conditions. J Control Release. 2010;148(1):e37-9.
42. Stepniak D, Spaenij-Dekking L, Mitea C, Moester M, de Ru A, Baak-Pablo R, et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol. 2006;291(4):G621-9.
43. Tack GJ, van de Water JM, Kooy-Winkelaar EM, van Bergen J, Meijer GA, von Blomberg BM, et al. Can prolyl endoprotease enzyme treatment mitigate the toxic effect of gluten in coeliac patients? Gastroenterology. 2010;138(5):S-54.
44. Siegel M, Garber ME, Spencer AG, Botwick W, Kumar P, Williams RN, et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci. 2012;57(2):440-50.
45. Adelman DC. Gluten degradation by ALV003, a novel drug in development for coeliac disease. 26th AOECS general assembly, international coeliac disease scientific conference - better life for coeliacs. 2012. 6.-9.09.2012, Helsinki, Finland (2012).
46. Shan L, Marti T, Sollid LM, Gray GM, Khosla C. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J. 2004;383(2):311-8.
47. Fuhrmann G, Leroux J-C. In vivo fluorescence imaging of exogenous enzyme activity in the gastrointestinal tract. Proc Natl Acad Sci U S A. 2011;108(22):9032-7.
48. Gass J, Ehren J, Strohmeier G, Isaacs I, Khosla C. Fermentation, purification, formulation, and pharmacological evaluation of a prolyl endopeptidase from Myxococcus xanthus: Implications for Celiac Sprue therapy. Biotechnol Bioeng. 2005;92(6):674-84.
49. Ehren J, Govindarajan S, Morón B, Minshull J, Khosla C. Protein engineering of improved prolyl endopeptidases for celiac sprue therapy. Protein Eng Des Sel. 2008;21(12):699-707.
50. Robic S. Alvine Pharmaceuticals Inc, USA, assignee. PEGylated Glutenase Polypeptides. Patent WO2007047303A2. 2007.
51. Gopalakrishnan S, Durai M, Kitchens K, Tamiz AP, Somerville R, Ginski M, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012;35(1):86-94.
52. Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, Leon F, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012;107(10):1554-62.
53. Ménard S, Lebreton C, Schumann M, Matysiak-Budnik T, Dugave C, Bouhnik Y, et al. Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease. Am J Pathol. 2012;180(2):608-15.
54. Mazumdar K, Alvarez X, Borda JT, Dufour J, Martin E, Bethune MT, et al. Visualization of transepithelial passage of the immunogenic 33-residue peptide from α-2 gliadin in gluten-sensitive macaques. PLoS One. 2010;5(4):e10228.
55. Siegel M, Khosla C. Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther. 2007;115(2):232-45.
56. Rauhavirta T, Oittinen M, Kivistö R, Männistö P, Garcia-Horsman J, Wang Z, et al. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol. doi: 10.1007/s10875-012-9745-5.
57. Szondy Z, Sarang Z, Molnár P, Németh T, Piacentini M, Mastroberardino PG, et al. Transglutaminase 2-/- mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. Proc Natl Acad Sci U S A. 2003;100(13):7812-7.
58. Hils M, Weber J, Buechold C, Pasternack R. Selective blockers of tissue transglutaminase for coeliac disease therapy. 26th AOECS general assembly, international coeliac disease scientific conference - better life for coeliacs. 2012. 6.-9.09.2012, Helsinki, Finland (2012).
59. van de Wal Y, Kooy YMC, van Veelen P, Vader W, August SA, Drijfhout JW, et al. Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol. 1999;29(10):3133-9.
60. Kapoerchan VV, Wiesner M, Overhand M, van der Marel GA, Koning F, Overkleeft HS. Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease. Bioorg Med Chem. 2008;16(4):2053-62.
61. Brar P, Lee S, Lewis S, Egbuna I, Bhagat G, Green PHR. Budesonide in the treatment of refractory celiac disease. Am J Gastroenterol. 2007;102(10):2265-9.
62. Daum S, Ipczynski R, Heine B, Schulzke JD, Zeitz M, Ullrich R. Therapy with budesonide in patients with refractory sprue. Digestion. 2006;73(1):60-8.
63. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 2005;52(9):2686-92.
64. Šenolt L, Vencovský J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmun Rev. 2009;9(2):102-7.
65. Costantino G, della Torre A, Lo Presti MA, Caruso R, Mazzon E, Fries W. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis. 2008;40(1):74-7.
66. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275.
67. Gauthier MA, Klok H-A. Polymer-protein conjugates: an enzymatic activity perspective. Polym Chem. 2010;1(9):1352-73.